Your browser does not support JavaScript or it may be disabled!
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
Get Realtime News
on your webpage

About 572 results for "Tecfidera"

Biogen profit rises 30% on higher Tecfidera sales

Biogen Inc reported a 30 percent rise in quarterly profit, driven by strong sales of its top-selling oral multiple sclerosis drug, Tecfidera. Net profit attributable to Biogen rose to $927.3 million, or $3.93 per share, in the second quarter ended ... Economic Times, 1 month ago

14 images for Tecfidera

Motley Fool, 3 weeks ago
KXXV-TV, 2 weeks ago
Sys-Con Media, 2 weeks ago, 2 weeks ago
Fidelity Brokerage Services LLC, 1 month ago
Motley Fool, 1 month ago
Proactive Investors USA, 1 month ago
Proactive Investors USA, 1 month ago
Seeking Alpha, 1 month ago
The Fiscal Times, 1 month ago

Biogen Second Quarter 2015 Revenues Increase 7% to $2.6 Billion

TECFIDERA ® now the most prescribed oral MS therapy globally Sites initiated for aducanumab Phase 3 studies for Alzheimer's disease CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Biogen Inc. (NASDAQ: BIIB) today reported second quarter ...
 CNBC1 month ago BIOGEN : Second Quarter 2015 Revenues Increase 7% to $2.6 Billion  4 Traders1 month ago Flex Pharma Reports Second Quarter 2015 Financial Results  TheStreet.com3 weeks ago Flex Pharma: Biogen's Dr. Alfred Sandrock Joins Scientific Advisory Board  Individual.com2 months ago
Proactive Investors USA

REUTERS - UPDATE 3-Biogen halves sales growth forecast as Tecfidera demand stalls

UPDATE 3-Biogen halves sales growth forecast as Tecfidera demand stalls Contributed by NAMPA / Reuters. * Tecfidera U.S. growth to be flat for rest of 2015 * Q2 MS drug sales miss estimates * Cuts FY sales growth view to 6-8 pct from 14-16 ...
 Namibia Press Agency1 month ago Biogen more than halves 2015 outlook guidance as Q2 sales disappoint; shares plummet  Proactive Investors USA1 month ago Biogen gets beaten up as slowing Tecfidera sales lead it to trim forecast  FiercePharma1 month ago UPDATE 3-Biogen halves sales growth forecast as Tecfidera demand stalls  Reuters1 month ago

Biogen's Big-Volume Plunge Marks End Of 5-Year Run

Biogen 's (NASDAQ: BIIB ) second-quarter earnings topped views, but its flagship drugs Tecfidera and Tysabri both missed sales expectations. That caused the biotech's quarterly revenue growth to come in well below consensus estimates. The company ...
 Investor's Business Daily1 month ago

Biogen cuts 2015 profit outlook as key MS drug sales slow

Biogen cut its full-year adjusted profit forecast Friday as sales of one of its multiple sclerosis drugs, Tecfidera, slow down. Shares dropped almost 17 percent in morning trading Friday. The biotechnology company now expects 2015 adjusted ...
 Miami Herald1 month ago

Biogen Tops Q2 Earnings, Cuts View on Tecfidera Issues

Biotech company, Biogen ( BIIB - Analyst Report ), reported second quarter 2015 earnings per share of $4.22 per share, well above the Zacks Consensus Estimate of $4.07 and 20.9% above the year-ago earnings. The company, however, missed on ...
 Zacks.com1 month ago Biogen Alert From Deutsche Bank: Tecfidera Could Hit Consensus Forecast  Benzinga.com1 month ago Biogen's Buy Rating Reiterated at Deutsche Bank (BIIB)  SleekMoney1 month ago
MedPage Today

Biogen (BIIB) Reports Second Non-Fatal Tecfidera PML Case 7/20/2015

July 17, 2015 By Mark Terry , Breaking News Staff Cambridge, Mass.-based Biogen, Inc. reported yesterday that a second patient taking the company's multiple sclerosis drug Tecfidera (dimethyl fumarate) has developed a ...
 ClinicSpace1 month ago Biogen confirms second PML case among Tecfidera patients  FiercePharma1 month ago Biogen Reports Second Non-Fatal Tecfidera PML Case  BioSpace1 month ago Tecfidera and PML  Multiple Sclerosis Trust1 month ago
Sys-Con Media

Biogen's Tecfidera And Other Orals Benefit As Increasingly Risk-Tolerant Neurologists Seek To Arrest Multiple Sclerosis (MS) Progression Sooner

_ Other key insights from the research While oral therapies such as Biogen's Tecfidera and Novartis' Gilenya are now being used in newly diagnosed and first switch patients, the fate of new non-oral agents has been mixed. Biogen's Plegridy, is the ...
 Sys-Con Media2 weeks ago
Medical Daily

Biogen Lowers Its Full-Year 2015 Outlook in 2Q15

Biogen's blockbuster drug Tecfidera registered much-lower-than-expected revenue growth, resulting in low full-year
 Yahoo! Canada3 weeks ago Biogen's Weak 2Q15 Tecfidera Performance Dampens Sentiment  Yahoo! Canada1 month ago Biogen's Multiple Sclerosis Drugs Show 2Q15 Growth  Yahoo! Finance1 month ago Biogen's Drop Looks Like Overreaction  Morningstar.com1 month ago

Biotech Stock Roundup: Biogen Down on Tecfidera Issues, Rege…

Several major biotech companies like Biogen ( BIIB - Analyst Report ), AbbVie ( ABBV - Analyst Report ), Celgene and Gilead reported second quarter results over the last five trading days. Biogen has been grabbing headlines for the wrong reasons ...
 Zacks.com1 month ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts


Realtime News

on your Webpage

Add Widget >Get your members hooked!
Related Queries - Tecfidera
Get updated on latest news & your favorite topics right in your inbox!
More     Less